Hananiya Daniel: JAK2 V617F and the Molecular Diagnosis of Polycythemia Vera
Hananiya Daniel, Medical Laboratory Scientist at Federal Medical Center Keffi, shared a post on LinkedIn:
“One Nucleotide Changed Everything: JAK2 V617F and the Molecular Diagnosis of Polycythemia Vera
What if a single change in DNA could alter the way blood cells are produced?
One example in hematology is the JAK2 V617F mutation.
At the DNA level, it is a G>T substitution at JAK2 c.1849, resulting in a change in the protein from valine to phenylalanine at position 617 — V617F.
One of the most important diseases associated with JAK2 V617F is polycythemia vera (PV).
PV is a chronic myeloproliferative neoplasm in which the bone marrow produces excessive blood cells, particularly red blood cells. It can also involve increased white blood cells and platelets.
The abnormal JAK2 signaling promotes blood-cell production even when normal regulatory signals should limit it.
The result can be erythrocytosis, increased blood viscosity and an increased risk of complications such as thrombosis and bleeding.
The important biomarkers
- Elevated Hemoglobin (Hb)
- Elevated Hematocrit (Hct)
- Red-cell mass, where available
- Serum erythropoietin (EPO) — often reduced
- JAK2 V617F
- JAK2 exon 12 mutations in appropriate JAK2 V617F-negative cases
Bone-marrow morphology
Where does molecular biology come in?
JAK2 V617F can be investigated using molecular techniques such as:
- Allele-specific PCR (AS-PCR)
- Real-time quantitative PCR
- Digital PCR
- NGS panels
- Sanger sequencing in appropriate applications
The WHO has evaluated reference materials for JAK2 V617F testing across approaches including allele-specific quantitative PCR, digital PCR, ARMS-PCR and NGS.
And if JAK2 V617F is not detected, the investigation does not necessarily stop.
Depending on the clinical and laboratory picture, additional molecular testing may include JAK2 exon 12, CALR and MPL variants.
Bioinformatics can help with:
Sequence quality control – alignment – variant calling – annotation – variant interpretation
NGS-based approaches can identify variants across multiple genes and help characterize the molecular landscape of myeloid neoplasms.
This is where laboratory medicine and computational biology increasingly converge.
The laboratory tells us what is happening in the blood.
Molecular biology helps explain what may be happening at the genetic level.
Bioinformatics helps us interpret the genomic information.
And hematopathology helps put the findings into their biological and diagnostic context.
The bigger lesson
The fascinating thing about JAK2 V617F is not simply that we can detect a mutation.
It is that we can trace a biological pathway:
DNA substitution
JAK2 V617F protein alteration
Abnormal JAK2 signaling
Clonal myeloid proliferation
Erythrocytosis more or less leukocytosis/thrombocytosis
Clinical and laboratory investigation
Molecular evidence supporting MPN diagnosis
One nucleotide. One molecular change. A much bigger biological story.”
Stay updated with Hemostasis Today.
-
Aug 24, 2026, 08:43Ann Muriuki։ How Freeze-Dried Plasma Could Reshape Emergency Trauma Care
-
Aug 24, 2026, 08:41Put thrombosis awareness in the spotlight this October 13! – World Thrombosis Day
-
Aug 24, 2026, 08:34Ashley George: Navigating Your DVT/PE Recovery Together
-
Aug 24, 2026, 08:07Mohamed Samier: DVT vs PE – Nursing Comparison Guide
-
Aug 24, 2026, 07:35Ahmed Alotaibi: How Common are Clinically Important Red Cell Antibodies in Pregnancy?
-
Aug 24, 2026, 06:47Help Shape the Future of Light Transmission Aggregometry – ISTH
-
Aug 24, 2026, 06:31Wolfgang Miesbach: How Common Are Fabricated References in Research?
-
Aug 24, 2026, 06:16Juan Manuel Cisneros Carrasco: When Blood Is Needed, Is It Actually There?
-
Aug 24, 2026, 04:02William Wallace: Does Fish Oil Increase Atrial Fibrillation Risk?